<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14D-1/A
TENDER OFFER STATEMENT
PURSUANT TO SECTION 14(D)(1) OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
AND
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
ENDOGEN, INC.
(Name of Subject Company)
EWOK ACQUISITION CORP.
PERBIO SCIENCE AB
PERSTORP AB
(Bidders)
COMMON STOCK, PAR VALUE $0.01
(Title of Class of Securities)
29264J 10 8
(Cusip Number of Class of Securities)
MAGNUS LINDQUIST
CHIEF FINANCIAL OFFICER
PERSTORP AB
SE-284 80 PERSTORP, SWEDEN
011-46-435-380-00
COPIES TO:
PATRICIA KAVEE MELICK, ESQ.
WIGGIN & DANA
THREE STAMFORD PLAZA
STAMFORD, CONNECTICUT 06911
(203) 363-7600
(Name, Address and Telephone Number of Persons Authorized to Receive
Notices and Communications on Behalf of Bidders)
MAY 27, 1999
(Date of Event which Requires Filing Statement on Schedule 13D)
<PAGE>
- --------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Ewok Acquisition Corp.
- --------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [_]
- --------------------------------------------------------------------------------
3. SEC USE ONLY
- --------------------------------------------------------------------------------
4. SOURCE OF FUNDS*
AF
- --------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f) [_]
- --------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts
- --------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 0
SHARES -----------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 1,259,772
OWNED BY -----------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER 0
REPORTING -----------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER 1,259,772
- --------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,259,772
- --------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [_]
- --------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
30.3%
- --------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- --------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
PerBio Science AB
- --------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [_]
- --------------------------------------------------------------------------------
3. SEC USE ONLY
- --------------------------------------------------------------------------------
4. SOURCE OF FUNDS*
AF
- --------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f) [_]
- --------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Sweden
- --------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 0
SHARES ------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 1,259,772
OWNED BY ------------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER 0
REPORTING ------------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER 1,259,772
- --------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,259,772
- --------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [_]
- --------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
30.3%
- --------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- --------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Perstorp AB
- --------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [_]
- --------------------------------------------------------------------------------
3. SEC USE ONLY
- --------------------------------------------------------------------------------
4. SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f) [__]
- --------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Sweden
- --------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 0
SHARES -----------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 1,259,772
OWNED BY -----------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER 0
REPORTING -----------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER 1,259,772
- --------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,259,772
- --------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [__]
- --------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
30.3%
- --------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
EXPLANATORY NOTE
This Amendment No. 2 to Tender Offer Statement on Schedule 14D-1/A and
Amendment No. 2 to Schedule 13D on Schedule 13D/A (collectively, along with the
original Schedule 14D-1 and Schedule 13D and Amendment No. 1 to the original
Schedule 14D-1 and Schedule 13D, the "Schedule 14D-1") relates to the offer by
Ewok Acquisition Corp., a Massachusetts corporation ("Purchaser") and a
wholly-owned subsidiary of PerBio Science AB, a Swedish corporation ("Parent"),
which is a direct wholly-owned subsidiary of Perstorp AB, a Swedish corporation
("Perstorp"), to purchase all outstanding shares of common stock, $.01 par value
per share (the "Shares"), of Endogen, Inc., a Massachusetts corporation (the
"Company"), at a price of $3.75 per Share, net to the seller in cash, upon the
terms and subject to the conditions set forth in the Purchaser's Offer to
Purchase, dated June 2, 1999 (the "Offer to Purchase"), as supplemented by the
Supplement to Offer to Purchase, dated June 17, 1999 (the "Supplement"), and the
related Letter of Transmittal, copies of which have been attached to the
Schedule 14D-1 as Exhibits (a)(1), (a)(10) and (a)(2), respectively.
Capitalized terms used, but not otherwise defined, herein have the
meanings ascribed to such terms in the Offer to Purchase, as amended by the
Supplement.
ITEM 10. ADDITIONAL INFORMATION.
The information set forth in Item 10(f) of the Schedule 14D-1 is hereby
amended and supplemented by the following information:
On June 30, 1999, Parent and Perstorp issued press releases announcing
the extension of the Expiration Date of the Offer until midnight, New York City
time, on Wednesday, July 7, 1999. The Offer was previously scheduled to expire
at midnight, New York City time, on Tuesday June 29, 1999. As of midnight on
June 29, 1999, approximately 3,040,712 Shares representing approximately 88% of
the total outstanding Shares were validly tendered and not withdrawn. Parent
and Perstorp indicated in the press releases that although Parent has
sufficient voting power to cause the merger of Purchaser with and into the
Company, Parent is extending the offer to obtain 90% of the Shares so that it
will be able to effect an immediate short-form merger under Massachusetts law.
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
(a)(11) Press Release of Parent, dated June 30, 1999.
(a)(12) Press Release of Perstorp, dated June 30, 1999.
<PAGE>
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: July 1, 1999
EWOK ACQUISITION CORP.
By: /s/ Robb Anderson
---------------------------------
Name: Robb Anderson
Title: President
PERBIO SCIENCE AB
By: /s/ Mats Fischier
---------------------------------
Name: Mats Fischier
Title: Director
PERSTORP AB
By: /s/ Ake Fredriksson
---------------------------------
Name: Ake Fredriksson
Title: President and Chief Executive
Officer
<PAGE>
EXHIBIT INDEX
(a)(11) Press Release of Parent, dated June 30, 1999.
(a)(12) Press Release of Perstorp, dated June 30, 1999.
<PAGE>
PERSTORP EXTENDS TENDER OFFER FOR
ENDOGEN, INC. TO JULY 7, 1999; 88%
OF ALL SHARES TENDERED
Rockford, Illinois, June 30, 1999 -- -- Perstorp AB subsidiary PerBio
Science AB today announced that it has extended until midnight, New York City
time, on Wednesday, July 7, 1999 its tender offer for all of the outstanding
shares of common stock of Endogen, Inc. ("Endogen"). As of 12:00 midnight, New
York City time, on Tuesday, June 29, 1999, approximately 3,040,712 shares
representing approximately 88% of the total outstanding Endogen common stock had
been validly tendered and not withdrawn pursuant to the tender offer.
Although PerBio Science AB already has more than sufficient voting
power to cause the merger of its subsidiary, Ewok Acquisition Corp., with and
into Endogen, PerBio Science is extending the offer to obtain 90% of Endogen's
outstanding shares (approximately, an additional 12,000 shares) so that it can
effect an immediate "short form" merger under Massachusetts law. If PerBio
Science AB is unable to obtain such additional shares, the merger will
nevertheless be effected, but will likely take up to two months to complete. In
either case, shareholders who have not tendered their shares must wait until
completion of the merger transaction before they will receive payment for their
shares. All shareholders, whether or not they have tendered their shares, will
receive $3.75 per share for their shares. In connection with this extension,
PerBio Science AB has agreed to permanently waive all of the remaining
conditions to the merger.
PerBio Science (the former Perstorp Life Science Division) is a
wholly-owned subsidiary of Perstorp AB, a global chemistry and materials
technology corporation located in Perstorp, Sweden. In October 1999, PerBio
Science AB is to be spun off to shareholders and listed on the Stockholm
Exchange.
<PAGE>
PERSTORP EXTENDS ACCEPTANCE PERIOD FOR ACQUISITION OF ENDOGEN, INC.
Perstorp AB subsidiary PerBio AB has extended the acceptance period for its
offer to acquire Endogen, Inc. through July 7.
At the end of the original acceptance period, June 29, owners of 3,040,712
shares, corresponding to 88% of the share capital and voting rights, had
accepted the offer.
PerBio is now extending the acceptance period with the aim of obtaining more
than 90% of the shares outstanding, to enable redemption of the remaining shares
through a simplified redemption procedure. The company intends to complete the
acquisition even if it does not acquire the targeted percentage of shares.
The amount offered per share remains unchanged at USD 3.75.
PerBio Science AB, a wholly owned subsidiary of Perstorp AB, is to be spun off
to Perstorp AB shareholders and listed on the Stockholm Stock Exchange in
October 1999. The company is active in the expansive biotechnology sector and
combines favorable profitability with high growth.
Endogen, Inc., which is listed on Nasdaq in New York and the Boston Stock
Exchange, has annual sales of approximately USD 10 million (approx. SEK 85
million). The company develops and manufactures biomedical research products for
use in both basic research and pharmaceutical drug discovery. The company's
products are used worldwide by research institutions and universities, as well
as pharmaceutical and biotechnology companies, in studies of such diseases as
cancer, immune defense disorders and AIDS. The acquired company will strengthen
PerBio Science's know-how in the biotechnology field, mainly by contributing
expertise in monoclonal antibody and recombinant DNA technology.
- -------------
For further information please contact Mats Fischier, Head of PerBio Science AB,
tel. +46 42-26 90 91 or Rolf Rahmberg, Vice President of Corporate
Communications, Perstorp AB, tel +46 435-381 59.
JUNE 30, 1999
PERSTORP AB
CORPORATE COMMUNICATIONS
